Adalimumab treatment in Crohn's disease does not induce early changes in regulatory T cells

TY - JOUR

T1 - Adalimumab treatment in Crohn's disease does not induce early changes in regulatory T cells

AU - Dige, Anders

AU - Hvas, Christian Lodberg

AU - Deleuran, Bent

AU - Kelsen, Jens

AU - Bendix-Struve, Mia

AU - Dahlerup, Jens Frederik

AU - Agnholt, Jørgen

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Abstract Objective. Anti-TNF-α antibodies has been suggested to modulate regulatory T cell (Treg) percentages in rheumatoid arthritis, but results from studies of Crohn's disease (CD) are conflicting. We investigated dynamic changes of circulating Tregs in CD during treatment with the anti-TNF-α-antibody adalimumab (Humira, Abbott Laboratories A/S, Emdrupvej 28C, DK-2100 Copenhagen). Material and methods. Blood samples from 26 CD patients were analysed using flow cytometry before and 1 and 26 weeks after initiation of adalimumab treatment to determine the percentage of Tregs among CD4+ T cells. Results. In spite of a significant decline in disease activity scores and biochemical markers of inflammation, during the first week of treatment, we did not observe early modulating effects of adalimumab on Treg percentages. However, we found a long-term increase in Treg percentages in responders who had low Treg percentages (

AB - Abstract Objective. Anti-TNF-α antibodies has been suggested to modulate regulatory T cell (Treg) percentages in rheumatoid arthritis, but results from studies of Crohn's disease (CD) are conflicting. We investigated dynamic changes of circulating Tregs in CD during treatment with the anti-TNF-α-antibody adalimumab (Humira, Abbott Laboratories A/S, Emdrupvej 28C, DK-2100 Copenhagen). Material and methods. Blood samples from 26 CD patients were analysed using flow cytometry before and 1 and 26 weeks after initiation of adalimumab treatment to determine the percentage of Tregs among CD4+ T cells. Results. In spite of a significant decline in disease activity scores and biochemical markers of inflammation, during the first week of treatment, we did not observe early modulating effects of adalimumab on Treg percentages. However, we found a long-term increase in Treg percentages in responders who had low Treg percentages (

U2 - 10.3109/00365521.2011.603157

DO - 10.3109/00365521.2011.603157

M3 - Journal article

C2 - 21793633

SN - 0036-5521

VL - 46

SP - 1206

EP - 1214

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

IS - 10

ER -